Background: Recent researches and relevant patents have been reported to prove the significant
value of Caveolin-1 (Cav-1) in cancer diagnosis and treatment.
Objective: Our study aimed to study the role of Cav-1 in gastric cancer progression and investigate the
relationship between Cav-1/E-cadherin expression and the clinical status of gastric cancer.
Method: Immunohistochemistry was applied to detect the expression of Cav-1 and E-cadherin in gastric cancer in a tissue
microarray. Real-time PCR was used to further detect the mRNA expression of Cav-1 and E-cadherin in tumor-derived and
peritumoral tissues and in different gastric cancer cell lines. The expression of E-cadherin was analyzed by Western Blot and
the cell migration ability was examined by Transwell migration assays after downregulation of Cav-1 using siRNA.
Results: The staining of Cav-1 and E-cadherin were both strong in all 5 of the normal gastric tissues, while in gastric cancer
tissues the staining of Cav-1 and E-cadherin were downregulated (44&33 negative, 21&22weak and 5&15 strong).
And their level was correlated with tumor clinical stage, pathological grade, and metastasis status. Moreover, there was a
positive correlation between Cav-1 expression and E-cadherin expression in gastric cancer tissues(r = 0.42, P < 0.05).
Knockdown of Cav-1 resulted in decreased expression of E-cadherin, cell morphology changes and elevated migration
ability of gastric cancer cells.
Conclusion: Decreased expression of Cav-1 and E-cadherin may play an important role in the progression of gastric cancer;
Knockdown of Cav-1 may promote EMT of gastric cancer by targeting E-cadherin.